Document is current

Any future updates will be listed below

801 The anti-tumor efficacy of immunogenic chemotherapy is enhanced by the dual A<sub>2a</sub>R/A<sub>2b</sub>R antagonist etrumadenant, relieving the necessity for an extended chemotherapy regimen

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0801

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark